Real-world management of treatment-naïve diabetic macular oedema in Japan: two-year visual outcomes with and without anti-VEGF therapy in the STREAT-DME study.
Masahiko ShimuraShigehiko KitanoDaisuke MuramatsuHarumi FukushimaYoshihiro TakamuraMakiko MatsumotoMasahide KokadoJiro KogoMariko SasakiYuki MorizaneOsamu KotakeTakashi KotoShozo SonodaTakao HiranoHiroto IshikawaYoshinori MitamuraFumiki OkamotoTakamasa KinoshitaKazuhiro KimuraMasahiko SugimotoKenji YamashiroYukihiko SuzukiTaiichi HikichiNoriaki WashioTomohito SatoKishiko OhkoshiHiroki TsujinakaSentaro KusuharaMineo KondoHitoshi TakagiToshinori MurataTaiji Sakamotonull nullPublished in: The British journal of ophthalmology (2019)
Following 2-year real-world management of treatment-naïve DME in Japan, BCVA improved by 2 letters. Eyes treated by anti-VEGF monotherapy showed a better visual prognosis than eyes receiving combination therapy. Despite treatment for DME being selected by specialists in consideration of medical and social factors, a satisfactory visual prognosis was not obtained, but final BCVA remained >20/40 in half of all eyes.